<DOC>
	<DOCNO>NCT01363206</DOCNO>
	<brief_summary>The study open-label , single arm single Center Phase II study evaluate safety efficacy combination Granulocyte Macrophage-Colony Stimulating Factor ( GM-CSF , Leukine ) Ipilimumab ( Yervoy ) therapy patient unresectable metastatic malignant melanoma .</brief_summary>
	<brief_title>Granulocyte Macrophage-Colony Stimulating Factor Ipilimumab Therapy Melanoma</brief_title>
	<detailed_description>The study open-label , single arm single Center Phase II study evaluate safety efficacy combination Granulocyte Macrophage-Colony Stimulating Factor ( GM-CSF , Leukine ) Ipilimumab ( Yervoy ) therapy patient unresectable metastatic malignant melanoma . The patient sample approximately 43 evaluable individual , male females 18 year age old measurable metastatic melanoma . Immunologic test do evaluate correlation clinical outcome . Patients treat 4 course GM-CSF ipilimumab administer every 3 week . GM-CSF administer subcutaneously daily 14 day dose 125 µg/m2 begin D1 21-day cycle . Ipilimumab intravenously dose 10 mg/kg , appropriate stopping/de-escalation rule . After initial 3 month ( 4 cycle ) treatment , GM-CSF administration continue 4 additional cycle schedule dose without ipilimumab 14 day every 21 day month 6 . Maintenance therapy begin month 6 consist ipilimumab dose administered end cycle 4 combine 14 day GM-CSF . Administration combination repeat every 3 month 2 year disease progression , whichever occur first . During maintenance phase , GM-CSF administer 14 day conjunction ipilimumab administer intervening time period .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Histologically confirm , ( surgically incurable unresectable ) stage III IV metastatic malignant melanoma . 2 . Prior systemic therapy metastatic disease permit required 3 . A minimum 1 measurable lesion accord irRC criterion . 4 . ECOG performance status 02 . 5 . Men woman , age ≥ 18 year . 6 . Adequate hematologic , renal liver function define laboratory value perform within 14 day prior initiation dose . WBC ≥ 2000/uL Absolute neutrophil count ( ANC ) ≥ 1000/uL Platelet count ≥ 50,000/uL Hemoglobin ≥ 8.0 g/dL Serum creatinine ≤ 3.0 x upper limit normal Total serum bilirubin ≤ 3.0 x upper limit normal ( except patient Gilbert 's Syndrome , must total bilirubin less 3.0 mg/dL LDH ≤ 4 time upper limit laboratory normal Serum aspartate transaminase ( ASAT/SGOT ) serum alanine transaminase ( ALAT/SGPT ) ≤ 2.5 time upper limit laboratory normal patient without liver metastasis Alkaline phosphatase ≤ 2.5 time upper limit normal , unless bone metastasis present absence liver metastases 7 . No active chronic infection HIV , Hepatitis B , Hepatitis C 8 . Patients must recover effect major surgery . 9 . Women childbearing potential ( WOCBP ) must use adequate method contraception avoid pregnancy throughout study 8 week study manner risk pregnancy minimize . WOCBP include female experienced menarche undergone successful surgical sterilization ( hysterectomy , bilateral tubal ligation bilateral oophorectomy ) postmenopausal . Postmenopausal define : Amenorrhea ≥ 12 consecutive month without another cause , For woman irregular menstrual period take hormone replacement therapy ( HRT ) , document serum follicle stimulate hormone ( FSH ) level ≥ 35mIU/mL ] . 1 . Brain metastasis treat stable least 1 month . 2 . History known spinal cord compression , carcinomatous meningitis , evidence symptomatic brain leptomeningeal disease screen CT MRI scan . 3 . Any malignancy patient diseasefree less 5 year , exception adequately treat cured basal squamous cell skin cancer , superficial bladder cancer carcinoma situ cervix . 4 . Autoimmune disease : Patients history inflammatory bowel disease exclude study patient history symptomatic disease ( e.g. , rheumatoid arthritis , systemic progressive sclerosis [ scleroderma ] , systemic lupus erythematosus , autoimmune vasculitis ( e.g. , Wegener 's Granulomatosis ) , motor neuropathy consider autoimmune origin ( e.g . GuillainBarré Syndrome ) . 5 . Any underlying medical condition , opinion Investigator , make administration study drug hazardous obscure interpretation AEs , condition associate frequent diarrhea . 6 . Psychological , familial , sociological geographical condition potentially hamper compliance study protocol followup schedule ; condition discuss patient trial entry . 7 . Any nononcology vaccine therapy use prevention infectious disease ( one month prior dose ipilimumab . 8 . A history prior treatment ipilimumab , CD137 agonist , CTLA4 inhibitor agonist ; GMCSF , monoclonal antibody . 9 . Concomitant therapy following : IL2 , interferon nonstudy immunotherapy regimens ; cytotoxic chemotherapy ; immunosuppressive agent ; investigation therapy ; chronic use systemic corticosteroid . 10 . Women childbearing potential ( WOCBP ) : unwilling unable use acceptable method avoid pregnancy entire study period least 8 week cessation study drug , positive pregnancy test baseline , pregnant breastfeed 11 . Prisoners subject compulsorily detain ( involuntarily incarcerate ) treatment either psychiatric physical ( e.g. , infectious ) illness 12 . Persons reproductive potential must agree use utilize adequate method contraception throughout treatment least 8 week study drug stop</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Melanoma</keyword>
	<keyword>GM-CSF</keyword>
	<keyword>Ipilimumab</keyword>
	<keyword>Immunologic Response</keyword>
</DOC>